Efficacy, safety, and cost of new anticancer drugs
BMJ
.
2002 Aug 3;325(7358):269-71.
doi: 10.1136/bmj.325.7358.269.
Authors
Silvio Garattini
1
,
Vittorio Bertele
Affiliation
1
Mario Negri Institute for Pharmacological Research, 20157 Milan, Italy. sgarattini@marionegri.it
PMID:
12153927
PMCID:
PMC1123779
DOI:
10.1136/bmj.325.7358.269
No abstract available
MeSH terms
Antineoplastic Agents* / adverse effects
Antineoplastic Agents* / economics
Antineoplastic Agents* / therapeutic use
Drug Approval
Drug Costs
Europe
Humans
Substances
Antineoplastic Agents